---
title: "ReShape Lifesciences (RSLS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RSLS.US.md"
symbol: "RSLS.US"
name: "ReShape Lifesciences"
industry: "Health Care Equipment"
datetime: "2026-05-20T12:35:48.605Z"
locales:
  - [en](https://longbridge.com/en/quote/RSLS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RSLS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RSLS.US.md)
---

# ReShape Lifesciences (RSLS.US)

## Company Overview

ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.63)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 165 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.92% |  |
| Net Profit YoY | 68.28% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 7175000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -120.16% | E |
| Profit Margin | -48.26% | E |
| Gross Margin | 61.19% | A |
| Revenue YoY | -13.92% | E |
| Net Profit YoY | 68.28% | A |
| Total Assets YoY | -21.24% | E |
| Net Assets YoY | -72.87% | E |
| Cash Flow Margin | 129.19% | B |
| OCF YoY | -13.92% | E |
| Turnover | 0.98 | A |
| Gearing Ratio | 81.03% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ReShape Lifesciences",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-13.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "68.28%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7175000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-120.16%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-48.26%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "61.19%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-13.92%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "68.28%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-21.24%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-72.87%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "129.19%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-13.92%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.98",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "81.03%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.20 | 109/183 | - | - | - |
| PB | 6.21 | 116/183 | 6.21 | 6.21 | 5.49 |
| PS (TTM) | 1.06 | 41/183 | 1.06 | 1.06 | 0.91 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RSLS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RSLS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RSLS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RSLS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**